INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by INVO Bioscience, Inc. on November 14, 2022. The filing serves to announce the company's financial results for the period ended September 30, 2022. The company is incorporated in Nevada and trades on The Nasdaq Stock Market LLC under the symbol "INVO."
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1, but the specific figures are not embedded in the body of this 8-K report.
Material Changes
No material changes versus the prior comparable period are detailed in this specific filing text. The document references the issuance of a press release regarding the third-quarter results but does not summarize the comparative performance data within the 8-K itself.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. It explicitly states that the information in Item 2.02 and the attached press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2022) for actual financial figures and operational highlights.
- Verify the company's cash position and burn rate, as these are critical for a biotechnology firm but are not listed in this summary document.
- Confirm the status of the company's clinical trials and regulatory milestones mentioned in the full press release.
- Check for any subsequent filings that may incorporate the press release data by reference.